{
  "id": 10426288,
  "title": "Zymeworks Issues Updated 2026 Financial Guidance",
  "url": "https://urgent.news/2026/09/28/zymeworks-issues-updated-2026-financial-guidance",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-28T10:36:59.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/zymeworks-issues-updated-2026-financial-guidance"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Zymeworks (ZYME) said the company now expects total revenue for 2026 to be between $278 million and $292 million and 2026 adjusted EBITDA to be between $114 million and $128 million, excluding the impact of any future transactions. The company announced the updated fi",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Financial Post",
        "title": "Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition",
        "url": "https://urgent.news/2026/09/28/zymeworks-announces-updated-2026-financial-guidance-and-final",
        "published": "2026-09-28T10:02:58.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}